ImmuCell Profit Margin 2006-2019 | ICCC
Current and historical gross margin, operating margin and net profit margin for ImmuCell (ICCC) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. ImmuCell net profit margin as of September 30, 2019 is -15.64%.
|ImmuCell Annual Profit Margins
|ImmuCell Quarterly Profit Margins
||Medical Products Manufacturing
ImmuCell Corp. is a biotechnology company striving to build shareholder value by commercializing proprietary technologies and helping dairy and beef producers and their veterinarians manage disease and reproduction in their herds. The company is also conducting an open label, efficacy study of DiffGAM, a human application of its milk-derived passive antibodytechnology for use as an alternative to antibiotics in the treatment and/or prevention of Clostridium difficile-associated diarrhea.